Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
RedactPHI
HIPAA-Compliant PHI Redaction
DetectICD10CM
ICD-10-CM Code Detection
Log in Register free account
1 code page views remaining. Guest accounts are limited to 1 page view. Register free account to get 5 more views.
Log in Register free account

Official Description

Radiopharmaceutical dacryocystography

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

Radiopharmaceutical dacryocystography is a specialized radiologic examination that focuses on the nasolacrimal ducts, commonly known as tear ducts. This procedure is conducted to evaluate conditions associated with excessive tearing and to assess the patency, or openness, of the lacrimal drainage system, as well as to identify any underlying pathologies. During the examination, a radioisotope labeled medium, which may include types such as Indium or Technetium 99m, is injected into the lacrimal system. Prior to the injection, anesthetic drops are applied to the eyes to minimize discomfort. The lacrimal canaliculi, which are small channels that drain tears from the eyes, are then cannulated to facilitate the introduction of the radioisotope. Following the injection, a series of radiographic images are captured at various oblique angles to visualize the lacrimal pathways effectively. The physician analyzes these images for signs of abnormalities, including stenosis (narrowing of the ducts), blockages, growths, or the presence of fistulae (abnormal connections). It is important to note that this CPT® code specifically reports the radiologic component of the dacryocystography procedure, and a comprehensive written report detailing the findings is generated for further evaluation and management.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

Radiopharmaceutical dacryocystography is indicated for the evaluation of various conditions related to the lacrimal drainage system. The following are the primary indications for this procedure:

  • Excessive Tearing This procedure is performed to investigate the underlying causes of excessive tearing, which may indicate dysfunction within the lacrimal drainage system.
  • Assessment of Patency The examination helps determine whether the nasolacrimal ducts are open and functioning properly, which is crucial for normal tear drainage.
  • Identification of Pathology The procedure is utilized to detect any pathological conditions affecting the lacrimal drainage system, such as stenosis, blockages, or abnormal growths.

2. Procedure

The procedure for radiopharmaceutical dacryocystography involves several key steps that ensure accurate imaging and assessment of the lacrimal drainage system. The following outlines the procedural steps:

  • Step 1: Anesthetic Application Anesthetic drops are instilled into the patient's eyes to minimize discomfort during the procedure. This step is essential to ensure patient comfort while the examination is conducted.
  • Step 2: Cannulation of Lacrimal Canaliculi The lacrimal canaliculi, which are small ducts that drain tears from the eyes, are cannulated. This involves the careful insertion of a small tube into the canaliculi to allow for the introduction of the radioisotope labeled medium.
  • Step 3: Injection of Radioisotope Labeled Medium A radioisotope labeled medium, such as Indium or Technetium 99m, is injected into the cannulated lacrimal system. This medium is crucial for visualizing the lacrimal pathways during imaging.
  • Step 4: Radiographic Imaging After the injection, a series of radiographic images are obtained at various oblique angles. These images are essential for visualizing the flow of the radioisotope through the lacrimal drainage system and identifying any abnormalities.
  • Step 5: Image Review and Reporting The physician reviews the radiographic images to assess for any evidence of pathology, such as stenosis, blockages, growths, or fistulae. A comprehensive written report of the findings is then generated for further evaluation.

3. Post-Procedure

After the completion of radiopharmaceutical dacryocystography, patients may be monitored briefly to ensure there are no immediate adverse reactions to the procedure. It is common for patients to experience some temporary discomfort or irritation in the eyes due to the anesthetic drops and the cannulation process. Patients are typically advised to avoid rubbing their eyes and to follow any specific post-procedure care instructions provided by the physician. The results of the procedure, as detailed in the written report, will guide further management and treatment options based on the findings observed during the examination.

Short Descr NUCLEAR EXAM OF TEAR FLOW
Medium Descr RADIOPHARMACEUTICAL DACRYOCYSTOGRAPHY
Long Descr Radiopharmaceutical dacryocystography
Status Code Active Code
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 1 - Diagnostic Tests for Radiology Services
Multiple Procedures (51) 0 - No payment adjustment rules for multiple procedures apply.
Bilateral Surgery (50) 0 - 150% payment adjustment for bilateral procedures does NOT apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 0 - Payment restriction for assistants at surgery applies to this procedure...
Co-Surgeons (62) 0 - Co-surgeons not permitted for this procedure.
Team Surgery (66) 0 - Team surgeons not permitted for this procedure.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Procedure or Service, Not Discounted when Multiple
ASC Payment Indicator Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS relative payment weight.
Type of Service (TOS) 4 - Diagnostic Radiology
Berenson-Eggers TOS (BETOS) I1E - Standard imaging - nuclear medicine
MUE 1
CCS Clinical Classification 209 - Radioisotope scan and function studies
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
GC This service has been performed in part by a resident under the direction of a teaching physician
MG The order for this service does not have applicable appropriate use criteria in the qualified clinical decision support mechanism consulted by the ordering professional
X5 Diagnostic services requested by another clinician: for reporting services by a clinician who furnishes care to the patient only as requested by another clinician or subsequent and related services requested by another clinician; this modifier is reported for patient relationships that may not be adequately captured by the above alternative categories; reporting clinician service examples include but are not limited to, the radiologist's interpretation of an imaging study requested by another clinician
Date
Action
Notes
Pre-1990 Added Code added.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"